Kyverna Therapeutics Inc. (KYTX)
NASDAQ: KYTX
· Real-Time Price · USD
3.01
-0.14 (-4.44%)
At close: Jun 17, 2025, 1:58 PM
-4.44% (1D)
| Bid | 2.98 |
| Market Cap | 130.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -145.42M |
| EPS (ttm) | -3.24 |
| PE Ratio (ttm) | -0.93 |
| Forward PE | -1.02 |
| Analyst | Buy |
| Ask | 3.02 |
| Volume | 117,366 |
| Avg. Volume (20D) | 336,560 |
| Open | 3.11 |
| Previous Close | 3.15 |
| Day's Range | 2.98 - 3.15 |
| 52-Week Range | 1.78 - 11.40 |
| Beta | 2.54 |
About KYTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KYTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KYTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+13.66%
Kyverna Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
11 months ago
+1.23%
Kyverna Therapeutics shares are trading higher after the company announced it received FDA Regenerative Medicine Advanced Therapy designation for KYV-101 in the treatment of patients with refractory stiff-person syndrome.
6 days ago · https://www.defenseworld.net
Squarepoint Ops LLC Acquires New Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)Squarepoint Ops LLC acquired a new stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm ...
